Is Claritas Pharmaceuticals Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Claritas Pharmaceuticals Inc (CLAS.H.V) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Claritas Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Claritas Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Claritas Pharmaceuticals Inc?

Muslim investors may consider investing in Claritas Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Claritas Pharmaceuticals Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Claritas Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Claritas Pharmaceuticals Inc updated?

The Shariah compliance status of Claritas Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Claritas Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Claritas Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Claritas Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Analyst's Ratings for Claritas Pharmaceuticals Inc (CLAS.H.V)

Based on 9 analysts giving stock ratings to Claritas Pharmaceuticals Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Claritas Pharmaceuticals Inc. Stock Analysis CLAS.H.V

Canada Health Care Nano Cap

Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in San Rafael California, California. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Key Statistics of Claritas Pharmaceuticals Inc (CLAS.H.V)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.03$0.03

Today's Open

$0.03

Volume

29.00K

P/E Ratio (TTM)

0.22

52 Week Range

$0.03$0.03

Market Cap

940.00K

Avg. Volume

Dividend Yield

Financial Metrics & Statements of Claritas Pharmaceuticals Inc (CLAS.H.V)

FAQ's for Claritas Pharmaceuticals Inc (CLAS.H.V)

According to Musaffa’s Shariah screening methodology, Claritas Pharmaceuticals Inc (CLAS.H.V) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.